Navigation Links
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Date:1/3/2008

six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

About VYVANSE

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if your child develops symptoms that suggest heart problems, such as chest pain or fainting.

VYVANSE should not be taken if your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking VYVANSE if your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if your child develops any of these conditions or symptoms while taking VYVANSE.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studie
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
2. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
3. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
4. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
5. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
6. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
7. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
8. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
9. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Boston Scientific Corporation (NYSE: BSX ) ... $2 billion aggregate principal amount of its senior notes ... offering consists of $850 million of 4.50 percent notes ... due January 2020 and $300 million of 7.375 percent ... use the net proceeds for general corporate purposes, including ...
(Date:12/14/2009)... has completed the delivery of Brookfield Engineering’s Powder Flow Tester ... enclosure with a smaller footprint and more compact design. ... ... 2009 -- ThermoFab, a US-based thermoforming company, has completed the ... move from sheet metal to a plastic enclosure with a ...
(Date:12/11/2009)... 2009 miRagen Therapeutics, Inc., a biopharmaceutical company ... microRNA-based therapeutics for cardiovascular and muscle disease, today ... (miR-206) plays a crucial role in the progression ... disease) and in neuromuscular synaptic regeneration in mice. ... issue of the journal Science , reveal ...
(Date:12/11/2009)... December 11 Algeta ASA (OSE: ... first clinical center in the,US, the Tulane ... patients,in the phase III clinical study of ... hormone-refractory) prostate cancer,(CRPC) that has metastasized to ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... U.S. Army,Research, Development and Engineering Command Acquisition Center, ... and Technical,Products a contract option worth approximately $43 ... Systems (JBPDS). The contract terms,also include field-support packages ... a modification of a 2004 contract and brings ...
... FRANCISCO, April 7, 2008 BioSpace, the world,s,leading ... fair company,is hosting a Private Label Career Fair ... Massachusetts. The event will be held at the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080222/CLF013LOGO ), Boehringer ...
... 7, 2008 /Xinhua-PRNewswire-FirstCall/ -- China YCT,International Group Inc. ... owned subsidiary, Shandong Spring Pharmaceutical Co., Ltd, has,entered ... Chun Tang,Bioengineering Co. Ltd., effective as of April ... will manage the operations of,Shandong Yong Chun Tang, ...
Other Biology Technology:U.S. Army Awards General Dynamics Contract for Biological Detection System Production and Support 2Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts 2China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier 2China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier 3
(Date:12/11/2009)... to identify and degrade the diverse types of defective ... The researchers Sabine C. Horn, Professor Thomas Sommer, Professor ... Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have ... an enzyme complex that plays a critical role in ... regulating the identification and disposal of various defectively produced ...
(Date:12/11/2009)... nearly two decades, Ivy Pike, an associate professor of ... ethnic groups in rural northern Kenya to understand how ... living there. , The results of her and her ... in three pastoralist communities of northern Kenya: A conceptual ... Social Science and Medicine , in collaboration with ...
(Date:12/11/2009)... discoveries about the deep ocean,s temperature variability and circulation ... , The deep ocean is affected more by surface ... more accurate predictions of factors such as sea level ... temperatures have also been found to result in a ... in a faster transport of large quantities of warm ...
Breaking Biology News(10 mins):MDC researchers identify a scaffold regulating protein disposal 2UA-led study grapples with health effects of low-intensity warfare 2New discoveries could improve climate projections 2Breckenridge Pharmaceutical Enters Agreement with Orit Laboratories 28West Caldwell NJ 29 to Market Ergocalciferol 28Vitamin D 29 Capsules 54676 1Breckenridge Pharmaceutical Enters Agreement with Orit Laboratories 28West Caldwell NJ 29 to Market Ergocalciferol 28Vitamin D 29 Capsules 54676 2Synthetic Protein Thwarts HIV Infection in Lab 54673 1Synthetic Protein Thwarts HIV Infection in Lab 54673 2Smoking Worsens Multiple Sclerosis 54670 1Smoking Worsens Multiple Sclerosis 54670 2Smoking Worsens Multiple Sclerosis 54670 3
... for the first time ever discovered DNA from living bacteria ... before has traces of still living organisms that old been ... of the ageing of cells and might even cast light ... being published in the current issue of PNAS (Proceedings of ...
... Special National Meeting Edition ,Aug. 22, 2007 , ... EMBARGOED FOR VARIOUS TIMES AS INDICATED , PressPac Archive: ... only: For full information about the Boston meeting, including ... abstracts of more than 9,500 scientific papers, and hundreds ...
... in the natural world but so too are cheats ... good but simply reap the benefits of others cooperative ... how cooperation persists despite the threat of cheat takeover ... of Edinburgh and Oxford have found that in bacteria, ...
Other Biology News:The world's oldest bacteria 2American Chemical Society's Weekly Press Pac 2American Chemical Society's Weekly Press Pac 3American Chemical Society's Weekly Press Pac 4American Chemical Society's Weekly Press Pac 5American Chemical Society's Weekly Press Pac 6American Chemical Society's Weekly Press Pac 7American Chemical Society's Weekly Press Pac 8American Chemical Society's Weekly Press Pac 9Social parasites of the smaller kind 2
Mouse monoclonal [J53] to Thyroid Hormone Receptor beta 1 ( Abpromise for all tested applications). entrezGeneID: 7068 SwissProtID: P10828...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
Request Info...
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Biology Products: